Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro

Japanese Journal of Cancer Research

Volumn 92, Issue 1, 2001, Pages 74-82

  Kano, Yasuhiko ^a   Akutsu, Miyuki ^a   Tsunoda, Saburo ^a   Suzuki, Kenichi ^a   Yazawa, Yasuo ^a   Furukawa, Yusuke ^b  

^a TOCHIGI CANCER CENTER   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Colon cancer; Isobologram; Methotrexate; Raltitrexed; Synergism

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; DNA; EDETIC ACID; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; IRINOTECAN; METHIONINE; METHOTREXATE; NUCLEOTIDE DERIVATIVE; OXALIPLATIN; PURINE DERIVATIVE; RALTITREXED; SODIUM CHLORIDE; TETRAHYDROFOLIC ACID; THYMIDINE PHOSPHATE; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; TRYPSIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL GROWTH; CELL INTERACTION; COLON CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EXPOSURE; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; SOLID TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; METHOTREXATE; QUINAZOLINES; THIOPHENES; TUMOR CELLS, CULTURED;

EID: 0035112478     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2001.tb01050.x     Document Type: Article

References (27)

1. Antifolates
2. Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors
3. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study
4. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors
5. 14C]raltitrexed in cancer patients
6. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer
7. Phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor
8. New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex')
9. Mature results from three large controlled studies with raltitrexed ('Tomudex')
10. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial
11. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer
12. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
13. In vitro effects of amsacrine in combination with other anti-cancer agents
14. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture
15. In vitro schedule-dependent interaction between raltitrexed and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines
16. Schedule-dependent interactions between raltitrexed and cisplatin in human carcinoma cell lines in vitro
17. Schedule-dependent interaction between raltitrexed and 5-fluorouracil in human colon cancer cell lines in vitro
18. Variable effects of the combination of tomudex (ZD1694) and cisplatin in ovarian cancer cell lines
19. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro
20. Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity
21. Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil
22. Enhanced 5-fluorouracil nucleotide formation following methotrexate: Biochemical explanation for drug synergism
23. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells
24. Cell cycle effects of antifolate antimetabolites: Implications for cytotoxicity and cytostasis
25. Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro
26. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
27. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results